Reports

Sale

Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

Global Phosphoinositide 3-Kinase Inhibitors Market Size: By Application: CLL - Chronic lymphocytic leukaemia, FL - Follicular lymphoma; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, Key Indicators for Demand, Key Indicators for Price; Competitive Landscape; 2024-2032

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook

The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% over the forecast period of 2024-2032.

 

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Targeted therapy for small molecules uses PI3K inhibitors that are relatively new in the area of oncology treatment. The development in the field of targeted therapy and their approvals are driving the growth of the industry globally. The governments across the nations have taken various measures to cut down the cost of these drugs to help patients. Such programmes help patients receive treatment at an affordable price. Thus, the emergence of such reimbursement schemes is one of the key market developments that will fuel the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

 

Market Segmentation

A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a therapeutic drug class that works by inhibiting one or more of the 3-kinase phosphoinositide enzymes.

 

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market By Application

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global phosphoinositide 3-kinase (PI3K) inhibitors industry can be broadly categorised based on its applications and regions.

  • Application
    • CLL - Chronic Lymphocytic Leukaemia
    • FL - Follicular Lymphoma
    • Others

The EMR report looks into the regional phosphoinositide 3-kinase (PI3K) inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The rising prevalence of cancer around the globe has resulted in the increased demand for chemotherapy and other treatment procedures. Chemotherapy drugs play a significant role in treating cancer. Their drawbacks, however, have produced a change from conventional chemotherapy to targeted therapies. As a result, extensive ongoing research is being performed on targeted therapies such as PI3K inhibitors with demonstrated effectiveness in oncology applications. Significant R&D has contributed to tailored treatments in the dominant therapeutic category. Thus, the recent launches and approvals of targeted therapy during the forecast period will contribute to the growth of phosphoinositide 3-kinase (PI3K) inhibitors industry globally. Although the complex manufacturing process of such drugs makes them expensive, which is becoming a significant challenge for manufacturers and may hamper the industry growth over the forecast period.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global phosphoinositide 3-kinase (PI3K) inhibitors market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Application
  • Region
Breakup by Application
  • CLL - Chronic lymphocytic leukaemia
  • FL - Follicular lymphoma
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Bayer AG
  • Gilead Sciences, Inc.
  • Novartis AG
  • TG Therapeutics, Inc.
  • Verastem, Inc.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market (2018-2023) 
    8.3    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast (2024-2032)
    8.4    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Application
        8.4.1    CLL - Chronic lymphocytic leukaemia
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    FL - Follicular lymphoma
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)   
    8.5    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Region
        8.5.1    North America
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Europe
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Asia Pacific
            8.5.3.1    Historical Trend (2018-2023)
            8.5.3.2    Forecast Trend (2024-2032)
        8.5.4    Latin America
            8.5.4.1    Historical Trend (2018-2023)
            8.5.4.2    Forecast Trend (2024-2032)
        8.5.5    Middle East and Africa
            8.5.5.1    Historical Trend (2018-2023)
            8.5.5.2    Forecast Trend (2024-2032)
9    North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
    9.1    United States of America
        9.1.1    Historical Trend (2018-2023)
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023)
        9.2.2    Forecast Trend (2024-2032)
10    Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023)
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023)
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023)
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East  and Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023)
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Bayer AG
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Gilead Sciences, Inc.
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Novartis AG
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    TG Therapeutics, Inc.
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    Verastem, Inc.
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    Others
16    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Key Industry Highlights, 2018 and 2032
2.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Application (USD Million), 2018-2023
3.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Application (USD Million), 2024-2032
4.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Region (USD Million), 2018-2023
5.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Region (USD Million), 2024-2032
6.    North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
7.    North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
8.    Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
9.    Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
10.    Asia Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
11.    Asia Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Latin America Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
13.    Latin America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Middle East and Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Middle East and Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Structure

Key Questions Answered in the Report

The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% between 2021 and 2026.

The major drivers of the industry, such as the rising prevalence of cancer, growing demand for targeted therapies, favourable government initiatives, and growing technological advancements, are expected to aid the market growth.

The key market trends guiding the growth of the phosphoinositide 3-kinase (PI3K) inhibitors industry include the ongoing research activities and fresh approval of targeted therapies.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

CLL (chronic lymphocytic leukaemia) and FL (follicular lymphoma) are the leading applications of phosphoinositide 3-kinase (PI3K) inhibitors in the industry.

The major players in the industry are Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.

Analyst Review

The global phosphoinositide 3-kinase (PI3K) inhibitors market is being driven by the growing cases of cancer, reimbursement schemes, and the growing demand for chemotherapy. Aided by the growing research and development activities, the market is expected to witness a healthy growth in the forecast period of 2024-2032, growing at a CAGR of 4.65%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on applications, the phosphoinositide 3-kinase (PI3K) inhibitors industry can be segmented into CLL (chronic lymphocytic leukaemia) and FL (follicular lymphoma). The major regional markets for phosphoinositide 3-kinase (PI3K) inhibitors are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER